Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Prolonged time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery is related to unimproved pathological response and poor survival prognosis for esophageal squamous cell carcinoma

Abstract

Background

The optimal time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery for esophageal squamous cell carcinoma remains unknown. This research aims to assess the impact of time interval on pathological response and survival prognosis.

Methods

Esophageal squamous cell carcinoma patients receiving neoadjuvant immunotherapy combined with chemotherapy followed by esophagectomy between January 2021 and March 2024 were included. The pathological response, survival outcomes, surgical outcomes, and postoperative complications were compared between the timely surgery group (time interval ≤ 6 weeks) and the delayed surgery group (time interval > 6 weeks).

Results

A total of 133 cases were included in this research. The pathological complete response (pCR) rates in timely surgery group and delayed surgery group were 23.4% and 12.8% (P = 0.167). There were no statistically significant differences between the two groups in terms of anastomotic fistula (P = 0.321), pulmonary infection (P = 0.427), chylothorax (P = 0.502), multiple organ dysfunction syndrome (P = 0.206), operation time (P = 0.359), blood loss (P = 0.093), number of resected lymph nodes (P = 0.091), hospital stay (P = 0.167), and R0 resection rate (P = 0.523). The 3-year overall survival (OS) rates were 77.5% in timely surgery group, and 63.5% in delayed surgery group (P = 0.046). The 3-year disease-free survival (DFS) rates were 59.1% and 38.4% in the two groups, respectively (P = 0.037). Additionally, multivariate Cox regression analyses indicated that the time interval from immunochemotherapy to surgery was independent prognostic factor for both OS (P = 0.049) and DFS (P = 0.025).

Conclusions

Prolonged time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery did not improve pCR rate and was associated with worse OS and DFS in esophageal squamous cell carcinoma.

Peer Review reports

Introduction

Esophageal carcinoma is a malignant tumor with high morbidity and mortality worldwide, causing a huge burden on human health [1]. Esophageal squamous cell carcinoma is the predominant pathological type of esophageal carcinoma, and is more common in Asia [2]. Due to the insidious symptoms of early esophageal carcinoma, many patients are diagnosed with tumor at the late stage or locally advanced stage, even losing the opportunity for surgery. According to guidelines, neoadjuvant therapy followed by esophagectomy has recommended as the standard treatment strategy for locally advanced esophageal squamous cell carcinoma [3], which helps to reduce tumor volume, control micrometastasis of tumor, improve complete surgical resection rate and survival prognosis.

Immunotherapy combined with chemotherapy is an important means of neoadjuvant therapy for esophageal squamous cell carcinoma, the safety and efficacy of which have been reported in numerous clinical researches. It has been revealed to have manageable toxic and side effect, downstaging tumor, increasing complete resection rate and pathological complete response (pCR) rate [4, 5]. The local changes in the tumor lesions, systemic inflammatory response of body, and the patient’s physical condition after neoadjuvant therapy can all influence the surgical outcomes. Notably, these factors may change over time. Therefore, the choice of surgical timing is particularly important for optimizing the effectiveness of tumor treatment. At present, there is no consensus on the optimal timing of surgery after neoadjuvant therapy for esophageal squamous cell carcinoma, and different studies have drawn inconsistent conclusions. Liu et al. [6] and Lee et al. [7] reported that a prolonged time interval from neoadjuvant chemoradiotherapy to surgery is related to a higher pCR rate, but it is not associated with survival prognosis. However, Nilsson et al. [8] pointed out in their clinical trial that prolonged interval between neoadjuvant chemoradiotherapy and surgery does not improve pCR rate, moreover, it is related with a trend towards poorer survival outcomes. Immunotherapy represented by PD-1/PD-L1 inhibitors blocks the interaction between PD-1 and PD-L1, relieving the inhibition of T cells and restoring their anti-tumor ability, whose tumor treatment mechanism is different from radiotherapy. Currently, the optimal surgical timing for neoadjuvant immunotherapy combined with chemotherapy has not been determined, despite many clinical trials on esophageal squamous cell carcinoma chose a time window of 4–6 weeks after the last neoadjuvant therapy for surgery [9,10,11]. In addition, there have been rare researches about the impact of prolonged time interval from neoadjuvant immunochemotherapy to surgery on tumor pathological response and survival prognosis in esophageal squamous cell carcinoma.

This study aimed to evaluate the impact of delayed surgery after immunotherapy combined with chemotherapy on pathological response and survival outcomes by comparing the clinicopathological and prognostic characteristics of esophageal squamous cell carcinoma patients with time interval from neoadjuvant immunochemotherapy to surgery time shorter than 6 weeks and longer than 6 weeks. This study provided evidence for determining the optimal surgical timing after neoadjuvant immunotherapy combined with chemotherapy in clinical practice.

Materials and methods

Study population

This research retrospectively reviewed esophageal squamous cell carcinoma patients receiving neoadjuvant immunotherapy combined with chemotherapy followed by esophagectomy between January 2021 and March 2024 in the First Affiliated Hospital of Xiamen University. Patients were included in this research if they met the following criteria: (1) patients diagnosed with esophageal squamous cell carcinoma on the basis of pathological examination; (2) patients undergoing neoadjuvant immunotherapy combined with chemotherapy followed by esophagectomy and lymphadenectomy; (3) patients with complete clinicopathological and follow-up information. The exclusion criteria were as follows: (1) patients who had or previously had other malignant tumors at the time of diagnosis of esophageal squamous cell carcinoma; (2) patients who received anti-tumor therapeutic strategies other than neoadjuvant immunotherapy combined with chemotherapy. The cases were divided into two groups based on time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery: timely surgery group (time interval ≤ 6 weeks) and delayed surgery group (time interval > 6 weeks).

Neoadjuvant therapy regimen and surgical process

The neoadjuvant chemotherapy regimens included albumin-bound paclitaxel plus nedaplatin, albumin-bound paclitaxel plus cisplatin, and albumin-bound paclitaxel plus carboplatin. The immunotherapy drugs included Camrelizumab, Sintilimab, Pembrolizumab, Tislelizumab, Toripalimab, Nivolumab, and Penpulimab. The detailed neoadjuvant therapy protocols and drug dosage were shown in Table S1. All enrolled esophageal squamous cell carcinoma patients underwent esophagectomy via minimally invasive three-incision McKeown operation procedures with standard two-field lymphadenectomy. The indication criteria for adjuvant therapy were as follows: (1) patients who have not reached pCR and (2) patients with cT3-4 or cN + stage.

Patients follow-up

We performed follow-up evaluations every three months for the first two years after esophagectomy, and every six months thereafter. Enhanced computed tomography scans of the neck, chest, and abdomen were performed for every patients at each outpatient visit. The follow-up endpoint was the date of death or August 15, 2024.

Treatment response and survival outcome assessment

The imaging evaluation of tumor treatment response was performed by the enhanced computed tomography scans and the imaging efficacy evaluation was based on the criteria for Response Evaluation Criteria in Solid Tumors (RECIST 1.1) [12]. The American Joint Committee on Cancer tumor-node-metastasis staging criteria (eighth edition) was used to determine the pathological stage of esophageal squamous cell carcinoma. The pCR was defined as the absence of evidence of residual tumor cells by pathological examination. The major pathological response (MPR) was defined as residual tumor cells of less than 10%. Additionally, the overall survival (OS) was defined as the time interval from the date of surgery to death or the date of last follow-up, and the disease-free survival (DFS) was defined as the time interval from the date of surgery to the recurrence of tumor or death.

Statistical analysis

Statistical analyses were performed using R 4.3.2 version and SPSS 26.0 software (SPSS Inc, Chicago, IL, USA). The chi-square test or Fisher exact probability test was conducted to compare categorical variables. Continuous variables were presented as means ± standard deviation and compared via independent sample t-test. In addition, the Kaplan–Meier method with the log-rank test were used to evaluate OS and DFS. The factors related to OS and DFS were determined through univariate and multivariate Cox proportional hazards regression models. A P value less than 0.05 was considered statistically significant.

Results

Baseline clinicopathological characteristics of the study cohort

A total of 133 esophageal squamous cell carcinoma patients who underwent neoadjuvant immunotherapy combined with chemotherapy followed by esophagectomy were finally included in this research. There were 106 males and 27 females, and the median age at the first time of neoadjuvant therapy was 60 years ranging from 44–79 years. As shown in Table 1 and Fig. 1, the median time interval between neoadjuvant immunochemotherapy and surgery was 5.14 weeks (range: 2.14–11.71 weeks). Except for more patients with cT4 stage were found in delayed surgery group (P = 0.017), there were no statistically significant differences in terms of sex (P = 0.364), age (P = 0.107), smoking history (P = 0.909), hypertension (P = 0.716), diabetes (P = 0.569), coronary atherosclerosis (P = 0.249), tumor location (P = 0.971), cN stage (P = 0.574), imaging response (P = 0.445), neoadjuvant therapy cycles (P = 0.768), neoadjuvant therapy regimen (P = 0.350), adjuvant therapy (P = 0.688), tumor size (P = 0.175), grade (P = 0.374), ypT stage (P = 0.734), and ypN stage (P = 0.829) between the timely surgery group and the delayed surgery group.

Table 1 Baseline characteristics of esophageal squamous cell carcinoma patients receiving neoadjuvant immunotherapy combined with chemotherapy followed by esophagectomy
Fig. 1
figure 1

Distribution histogram of time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery in esophageal squamous cell carcinoma

Pathological response assessment

In the entire cohort, there were 85 patients achieving partial response and 48 patients assessed as stable disease on the basis of imaging examination, with an objective response rate of 63.9%. Moreover, 53 people (39.8%) achieved MPR, of which 27 people (20.3%) achieved pCR in this research (Table 2). There were 7 (17.9%), 8 (20.5%), 10 (25.6%), and 14 (35.9%) patients achieving TRG0, TRG1, TRG2, and TRG3 pathological response in the delayed surgery group compared with 25 (26.6%), 13 (13.8%), 29 (30.9%), and 27 (28.7%) patients in the timely surgery group, respectively. In addition, the pCR rates were 23.4% and 12.8% in the timely surgery group and the delayed surgery group, respectively, without significant statistical difference (P = 0.167). And the MPR rates were 40.4% and 38.5% in these two cohorts without significant statistical difference either (P = 0.833) (Fig. 2).

Table 2 The pathological response between timely surgery group and delayed surgery group in esophageal squamous cell carcinoma patients
Fig. 2
figure 2

The distribution condition of pathological complete response (A) and major pothalogical response (B) between the timely surgery group and the delayed surgery group

Adverse reactions and surgical outcomes

As shown in Table 3, there were no statistically significant differences between the timely surgery group and the delayed surgery group in terms of anemia (P = 0.898), leukopenia (P = 0.645), thrombocytopenia (P = 0.664), liver dysfunction (P = 0.590), renal dysfunction (P = 0.431), skin rash (P = 0.650), and pneumonia (P = 0.150). In addition, no statistically significant differences were found in terms of anastomotic fistula (P = 0.321), pulmonary infection (P = 0.427), chylothorax (P = 0.502), and multiple organ dysfunction syndrome (P = 0.206) between the two groups.

Table 3 Adverse reactions and postoperative complications between timely surgery group and delayed surgery group in esophageal squamous cell carcinoma patients

As shown in Table 4, there were no significant statistical differences between the timely surgery group and the delayed surgery group regarding operation time (309.04 ± 87.71 min vs. 296.92 ± 82.04 min, P = 0.359), blood loss (149.68 ± 105.85 ml vs. 173.59 ± 159.08 ml, P = 0.093), number of resected lymph nodes (25.01 ± 10.14 vs. 24.87 ± 7.23, P = 0.091), and hospital stay (18.77 ± 11.95 days vs. 21.41 ± 6.96 days, P = 0.167). Moreover, the R0 resection rates were 93.6% and 92.3% in the timely surgery group and the delayed surgery group, respectively, without statistically significant difference (P = 0.523).

Table 4 Operative characteristics between timely surgery group and delayed surgery group in esophageal squamous cell carcinoma patients

Factors related to survival prognosis

In the entire cohort, the median follow-up time of esophageal squamous cell cercinoma patients was 19 months (range: 2–47 months). As presented in Fig. 3, the 1-year, 2-year, and 3-year OS rates were 92.8%, 85.7%, and 77.5% in the timely surgery group, and 89.2%, 63.5%, and 63.5% in the delayed surgery group, respectively, with statistically significant differences (P = 0.046). Additionally, The 1-year, 2-year, and 3-year DFS rates were 93.3%, 72.3%, and 59.1% in the timely surgery group, and 74.8%, 56.4%, and 38.4% in the delayed surgery group, respectively, also with statistically significant differences (P = 0.035). Furthermore, we conducted subgroup analyses based on cN stage and tumor size (Fig. 4). In the cN + stage subgroup, patients in the delayed surgery group had significantly poorer overall survival prognosis compared to those in the timely surgery group (P = 0.035). Additionally, delayed surgery significantly decreased OS (P = 0.040) and DFS (P = 0.007) in the subgroup of patients with tumor size larger than 5 cm.

Fig. 3
figure 3

Kaplan–Meier survival analysis of overall survival (A) and disease-free survival (B) between the timely surgery group and the delayed surgery group

Fig. 4
figure 4

Kaplan–Meier survival analysis according to cN stage and tumor size between the timely surgery group and the delayed surgery group. A Comparison of overall survival between the two groups for patients with cN0 stage. B Comparison of overall survival between the two groups for patients with cN + stage. C Comparison of disease-free survival between the two groups for patients with cN0 stage. D Comparison of disease-free survival between the two groups for patients with cN + stage. E Comparison of overall survival between the two groups for patients with tumor size less than 5 cm. F Comparison of overall survival between the two groups for patients with tumor size larger than 5 cm. G Comparison of disease-free survival between the two groups for patients with tumor size less than 5 cm. H Comparison of disease-free survival between the two groups for patients with tumor size larger than 5 cm

We further performed univariate and multivariate Cox regression analyses to determine the independent prognostic factors for esophageal squamous cell carcinoma patients receiving neoadjuvant immunotherapy combined with chemotherrapy. As shown in Table 5, interval from neoadjuvant therapy to surgery (P = 0.049) and ypN stage (P = 0.020) were independent prognostic factors for OS. Moerover, interval from neoadjuvant therapy to surgery (P = 0.025) and MPR status (P = 0.044) were independent predictors for DFS.

Table 5 Univariate and multivariate Cox regression analyses of overall survival and disease-free survival for esophageal squamous cell carcinoma patients

We conducted additional analysis based on different cutoff values of time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery, namely 4-week, 5-week, 7-week, and 8-week. We observed similar trends in baseline clinicopathological characteristics, pathological response, adverse reactions, surgical outcomes, and survival outcomes as when the cutoff value was set at 6-week (Table S2-S9 and Figure S1).

Discussion

Neoadjuvant therapy has been recommended as the standard treatment for locally advanced esophageal squamous cell carcinoma, and its optimal strategy and specific details have always been the focus of clinical researches. Among numerous related issues, the optimal surgical timing after neoadjuvant therapy has not been well elucidated. There have been many studies reporting the impact of time interval between neoadjuvant chemoradiotherapy and surgery on the pathological response and survival prognosis in esophageal carcinoma, but the conclusions of these studies vary greatly. Some researches found that the time interval from neoadjuvant chemoradiotherapy to surgery is not associated with pCR rate or OS in esophageal carcinoma [13, 14]. Nilsson et al. [8] and Chiu et al. [15] even revealed that prolonged time interval does not improve pCR rate, and may indicate a worse survival prognosis. However, some studies reported that prolonged time interval is associated with a higher pCR rate, despite no improvement in survival prognosis is found [7, 16,17,18]. Immunotherapy combined with chemotherapy is an important neoadjuvant therapeutic strategy for esophageal squamous cell carcinoma with a tumor treatment mechanism different from chemoradiotherapy, the optimal surgical intervention timing after which has not been fully understood. Whether delayed surgery has an impact on tumor pathological response and survival outcomes remains unknown. Moreover, there are fewer researches clarifying this issue.

In this research, we found that there were no statistically significant differences in MPR rate and pCR rate between the delayed surgery group and the timely surgery group. However, it was worth noting that the pCR rate in the delayed surgery group was 12.8%, lower than that of 23.4% in the timely surgery group. In a study investigating the impact of time interval from neoadjuvant immunotherapy to surgery for esophageal squamous cell carcinoma, Yang et al. [19] revealed that the rate of pCR is 34.1% in the timely surgery group and 24.6% in the delayed surgery group, despite no statistically significant difference is found. The results of this study was consistent with our findings. However, Liu et al. [20] pointed out that the pCR rate in the long-interval group is slightly higher than that in the short-interval group without statistically significant difference for esophageal squamous cell carcinoma patients receiving neoadjuvant camrelizumab combined with chemotherapy. On the basis of previous literature and our research findings, we speculate that prolonged time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery is not beneficial for improving the pCR rate in esophageal squamous cell carcinoma. Considering that a longer time interval may pose a risk of local lesion progression, tumor patients should avoid delaying surgery as much as possible.

There were abundant evidences regarding the relationship between the timing of surgery after neoadjuvant chemoradiotherapy and survival outcomes. Many researchers believed that prolonged time interval from neoadjuvant chemoradiotherapy to surgery is not conducive to improving the survival prognosis of esophageal carcinoma patients [6, 8, 21]. However, there was also literature that proposed a different viewpoint. Ruol et al. [22] pointed out that delaying surgery up to 90 days can reduce recurrence of tumor, and may improve OS in thoracic esophageal squamous cell carcinoma patients with R0 resection surgery. At present, there were limited reports on the optimal surgery timing after neoadjuvant immunotherapy combined with chemotherapy in esophageal squamous cell carcinoma. Existing literature all revealed that a longer time interval from neoadjuvant immunochemotherapy to surgery is associated with poorer survival outcomes [19, 20]. One reason for this result may be that patients often experience delayed surgery due to their poor physical condition, which is an important factor affecting survival outcomes. Except that 29 patients who received delayed surgery due to personal reasons, in our research, there were 3, 4, 2, and 1 patients with time interval from neoadjuvant therapy to surgery over 6 weeks due to pulmonary inflammation, leukopenia, liver dysfunction, and kidney dysfunction, respectively, which may affect the clinical outcomes. In addition, a longer time interval after neoadjuvant therapy may be a risk factor for tumor progression and metastasis [15]. In our research, we also found that a time interval longer than 6 weeks is significantly related with worse OS and DFS. Further subgroup analysis results showed that prolonged time interval was significantly associated with poor survival prognosis in patients with higher clinical lymph node staging and larger tumor lesion. Thus, we conclude that esophageal squamous cell carcinoma patients should avoid delaying surgery after neoadjuvant immunotherapy combined with chemotherapy, especially for those with more severe local tumor lesions.

In our study, we did not find a significant correlation between time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery and surgical difficulty or incidence of postoperative complications. Liu et al. [20] also indicated that there is no significant differences in the postoperative complications between the delayed surgery and timely surgery groups in esophageal squamous cell carcinoma. However, Overtoom et al. [23] revealed that prolonged time to surgery increases the risk of postoperative respiratory complications for esophageal carcinoma patients after neoadjuvant chemoradiotherapy. Wang et al. [24] found that a longer time interval from neoadjuvant chemoradiotherapy to surgery is related to higher risk of anastomotic fistula. This issue requires further clinical trials to investigate.

There have some limitations in our research. Firstly, this was a retrospective study, and potential bias was inevitable. Secondly, the sample size of our research was not large and it is a single center study, which may lead to a decrease in statistical power. Thirdly, the cut-off points of the time interval from neoadjuvant therapy to surgery for various researches were not the same. We set the cut-off point of 6 weeks, used by most clinical trials, which may lead to potential bias. Finally, the follow-up time in our research was relatively short, and further study is required to investigate the long-term survival outcomes.

Conclusion

Prolonged time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery did not improve pCR rate for esophageal squamous cell carcinoma. Instead, delayed surgery after neoadjuvant immunochemotherapy was significantly associated with worse OS and DFS. Esophageal squamous cell carcinoma patients should avoid delaying surgery if their physical conditions permit.

Data availability

All data generated or analysed during this study are included in this published article and its supplementary information files.

References

  1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin. 2024;74:229–63.

    Article  PubMed  Google Scholar 

  2. Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from globocan 2020. Gastroenterology. 2022;163:649–58.

    Article  PubMed  Google Scholar 

  3. Ajani JA, D’Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Ne. 2023;21:393–422.

    Article  Google Scholar 

  4. Yang W, Xing X, Yeung SJ, Wang S, Chen W, Bao Y, et al. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10: e003497.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ge F, Huo Z, Cai X, Hu Q, Chen W, Lin G, et al. Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic review and meta-analysis. Jama Netw Open. 2022;5: e2239778.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Liu J, Zeng X, Zhou X, Xu Y, Ding Z, Hu Y, et al. Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer. Oncol Lett. 2023;25:155.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Lee A, Wong AT, Schwartz D, Weiner JP, Osborn VW, Schreiber D. Is there a benefit to prolonging the interval between neoadjuvant chemoradiation and esophagectomy in esophageal cancer? Ann Thorac Surg. 2016;102:433–8.

    Article  PubMed  Google Scholar 

  8. Nilsson K, Klevebro F, Sunde B, Rouvelas I, Lindblad M, Szabo E, et al. Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial. Ann Oncol. 2023;34:1015–24.

    Article  CAS  PubMed  Google Scholar 

  9. Yang Y, Liu J, Liu Z, Zhu L, Chen H, Yu B, et al. Two-year outcomes of clinical N2–3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study. J Thorac Cardiov Sur. 2024;167:838–47.

    Article  Google Scholar 

  10. Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H, et al. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10(3):e004291.

  11. Yan X, Duan H, Ni Y, Zhou Y, Wang X, Qi H, et al. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE). Int J Surg. 2022;103: 106680.

    Article  PubMed  Google Scholar 

  12. Schwartz LH, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. Recist 1.1-update and clarification: from the recist committee. Eur J Cancer. 2016;62:132–7.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Klevebro F, Nilsson K, Lindblad M, Ekman S, Johansson J, Lundell L, et al. Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study. Dis Esophagus. 2020;33:doz078.

    Article  PubMed  Google Scholar 

  14. Tessier W, Gronnier C, Messager M, Hec F, Mirabel X, Robb WB, et al. Does timing of surgical procedure after neoadjuvant chemoradiation affect outcomes in esophageal cancer? Ann Thorac Surg. 2014;97:1181–9.

    Article  PubMed  Google Scholar 

  15. Chiu CH, Chao YK, Chang HK, Tseng CK, Chan SC, Liu YH, et al. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome? Ann Surg Oncol. 2013;20:4245–51.

    Article  PubMed  Google Scholar 

  16. Shaikh T, Ruth K, Scott WJ, Burtness BA, Cohen SJ, Konski AA, et al. Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. Ann Thorac Surg. 2015;99:270–6.

    Article  PubMed  Google Scholar 

  17. Haisley KR, Laird AE, Nabavizadeh N, Gatter KM, Holland JM, Vaccaro GM, et al. Association of intervals between neoadjuvant chemoradiation and surgical resection with pathologic complete response and survival in patients with esophageal cancer. Jama Surg. 2016;151: e162743.

    Article  PubMed  Google Scholar 

  18. Maramara T, Shridhar R, Blinn P, Huston J, Meredith K. Timing after neoadjuvant therapy predicts mortality in patients undergoing esophagectomy: a propensity score-matched analysis. J Gastrointest Surg. 2023;27:2342–51.

    Article  PubMed  Google Scholar 

  19. Yang G, Hong Y, Zhang X, Zeng C, Tan L, Zhang X. Impact of the interval between neoadjuvant immunotherapy and surgery on prognosis in esophageal squamous cell carcinoma (ESCC): a real-world study. Cancer Immunol Immun. 2024;73:202.

    Article  CAS  Google Scholar 

  20. Liu J, Zhu L, Huang X, Lu Z, Wang Y, Yang Y, et al. Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma? J Cancer Res Clin. 2024;150:161.

    Article  CAS  Google Scholar 

  21. Tie H, He F, Shen J, Zhang B, Ye M, Chen B, et al. Prolonged interval between neoadjuvant chemoradiotherapy and esophagectomy does not benefit the outcome in esophageal cancer: a systematic review and meta-analysis. Dis Esophagus. 2018;31:1–9.

    Article  CAS  PubMed  Google Scholar 

  22. Ruol A, Rizzetto C, Castoro C, Cagol M, Alfieri R, Zanchettin G, et al. Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome? Ann Surg. 2010;252:788–96.

    Article  PubMed  Google Scholar 

  23. Overtoom H, Eyck BM, van der Wilk BJ, Noordman BJ, van der Sluis PC, Wijnhoven B, et al. Prolonged time to surgery in patients with residual disease after neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg. 2024. https://doi.org/10.1097/SLA.0000000000006488. Epub ahead of print.

  24. Wang J, de Jongh C, Wu Z, de Groot EM, Alexandre C, Markar SR, et al. Impact of preoperative time intervals for neoadjuvant chemoradiotherapy on short-term postoperative outcomes of esophageal cancer surgery: a population-based study using the dutch upper gastrointestinal cancer audit (DUCA) data. Ann Surg. 2024;280:808–16.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by Natural Science Foundation of Fujian Province (No. 2022J05301 and No.2021J05284).

Funding

This study was supported by Natural Science Foundation of Fujian Province (No. 2022J05301 and No.2021J05284).

Author information

Authors and Affiliations

Authors

Contributions

Guanzhi Ye: Conceptualization; Literature selection; Data curation; Writing-review and editing. Gaojian Pan: Data extraction; Data curation; Software. Xiaolei Zhu: Conceptualization; Data curation; Writing-review and editing. Hongming Liu: Methodology; Literature selection. Ning Li: Data extraction; Literature selection. Guojun Geng: Conceptualization; Supervision; Writing-review and editing. Jie Jiang: Conceptualization; Supervision.All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Guojun Geng or Jie Jiang.

Ethics declarations

Ethics approval and consent to participate

This study complied with the Declaration of Helsinki and was approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University on 26 February 2024 (protocol number: XMYY-2024KYSB090). Due to the retrospective character of this analysis and the approval by the Ethics Committee of the First Affiliated Hospital of Xiamen University, the need for informed consent to participate was unnecessary.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

12876_2025_3802_MOESM1_ESM.tif

Supplementary Material 1: Figure S1. Kaplan–Meier survival analysis according to different time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery. (A) Comparison of overall survival between patients with time interval ≤ 4 weeks and patients with time interval > 4 weeks. (B) Comparison of disease-free survival between patients with time interval ≤ 4 weeks and patients with time interval > 4 weeks. (C) Comparison of overall survival between patients with time interval ≤ 5 weeks and patients with time interval > 5 weeks. (D) Comparison of disease-free survival between patients with time interval ≤ 5 weeks and patients with time interval > 5 weeks. (E) Comparison of overall survival between patients with time interval ≤ 7 weeks and patients with time interval > 7 weeks. (F) Comparison of disease-free survival between patients with time interval ≤ 7 weeks and patients with time interval > 7 weeks. (G) Comparison of overall survival between patients with time interval ≤ 8 weeks and patients with time interval > 8 weeks. (H) Comparison of disease-free survival between patients with time interval ≤ 8 weeks and patients with time interval > 8 weeks.

Supplementary Material 2.

Supplementary Material 3.

Supplementary Material 4.

Supplementary Material 5.

Supplementary Material 6.

Supplementary Material 7.

Supplementary Material 8.

Supplementary Material 9.

Supplementary Material 10.

Supplementary Material 11.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ye, G., Pan, G., Zhu, X. et al. Prolonged time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery is related to unimproved pathological response and poor survival prognosis for esophageal squamous cell carcinoma. BMC Gastroenterol 25, 223 (2025). https://doi.org/10.1186/s12876-025-03802-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12876-025-03802-5

Keywords